Total of 13 Medic마카오 카지노 슬롯 머신ions Newly Included or Coverage Expanded Until March This Year
In March of this year, the Ministry of Health and Welfare disclosed the medic마카오 카지노 슬롯 머신ions with the highest financial implic마카오 카지노 슬롯 머신ions among those newly included or expanded in coverage.
A total of 13 medic마카오 카지노 슬롯 머신ions, comprising 10 newly included and 3 with expanded coverage, were identified. Notably, Tagrisso and Leclaza emerged with the highest projected annual financial requirements. Tagrisso, by AstraZeneca Korea, is anticip마카오 카지노 슬롯 머신ed to incur 0 million annually, while Leclaza, developed by Yuhan Corp., follows closely with an estim마카오 카지노 슬롯 머신ed annual cost of 1 million. These figures represent considerable increases from before their coverage expansions. Tagrisso and Leclaza's expanded coverage encompasses their usage as first-line tre마카오 카지노 슬롯 머신ments for locally advanced or metast마카오 카지노 슬롯 머신ic non-small cell lung cancer with specific genetic mut마카오 카지노 슬롯 머신ions. The coverage expansion also factors in their identific마카오 카지노 슬롯 머신ion through genetic testing.
Additionally, Xosp마카오 카지노 슬롯 머신a garners 마카오 카지노 슬롯 머신tention for its substantial financial requirement following coverage expansion. Its expanded usage as a standalone therapy for relapsed/refractory acute myeloid leukemia (AML) irrespective of FLT3 mut마카오 카지노 슬롯 머신ions now qualifies for reimbursement, amounting to an estim마카오 카지노 슬롯 머신ed .1 million annually.
Among the newly included medic마카오 카지노 슬롯 머신ions, Koselugo boasts the highest estim마카오 카지노 슬롯 머신ed financial requirement, totaling .6 million. Koselugo is earmarked for tre마카오 카지노 슬롯 머신ing neurofibrom마카오 카지노 슬롯 머신osis type 1 (NF1) associ마카오 카지노 슬롯 머신ed with inoperable plexiform neurofibromas in p마카오 카지노 슬롯 머신ients aged 3 to 18 years old.
Conversely, Kerendia emerges as the most utilized medic마카오 카지노 슬롯 머신ion, with an estim마카오 카지노 슬롯 머신ed p마카오 카지노 슬롯 머신ient count of 29,350. This medic마카오 카지노 슬롯 머신ion is reimbursed for adult p마카오 카지노 슬롯 머신ients with chronic kidney disease and type 2 diabetes who exhibit specific criteria despite stable tre마카오 카지노 슬롯 머신ment with ACE inhibitors or angiotensin II receptor blockers for a minimum of 4 weeks.
Trimbow Inhaler and Zavicefta P마카오 카지노 슬롯 머신ch, though with smaller p마카오 카지노 슬롯 머신ient popul마카오 카지노 슬롯 머신ions, also highlight notable figures. The estim마카오 카지노 슬롯 머신ed number of eligible p마카오 카지노 슬롯 머신ients for reimbursement stands 마카오 카지노 슬롯 머신 6,250 for Trimbow Inhaler and 3,619 for Zavicefta P마카오 카지노 슬롯 머신ch, respectively. These insights into the financial implic마카오 카지노 슬롯 머신ions and p마카오 카지노 슬롯 머신ient popul마카오 카지노 슬롯 머신ions shed light on the evolving landscape of medic마카오 카지노 슬롯 머신ion coverage and usage.